D. Waters, L. Higginson, P. Gladstone, B. Kimball, M. Le May, S.J. Boccuzzi, J. Lesp}rance, Canadian Coronary Atherosclerosis Intervention Trial Study Group, "Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by seral quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial," Circulation, 89:959-68, 1994. (Cited in nearly 60 publications as of February 1996)

Comments by David Waters, Hartford Hospital, Connecticut

Cholesterol-lowering drugs have become a multimillion-dollar industry over the past decade. Medications such as lovastatin, which inhibits the action of the enzyme HMG-CoA reductase, are widely prescribed by physicians for people with extremely high cholesterol. Yet how these drugs affect coronary atherosclerosis-a condition directly linked to abnormally high cholesterol levels-had not been fully characterized by clinicians.

Dave Waters
HEART SMART: Results from a cholesterol-drug trial headed by David Waters show benefits for many groups.
This paper describes the first set of findings from...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?